Medicare And Alzheimer’s Drugs: Recent NCDs Mainly Omit Research Requirement, Biogen Notes
Executive Summary
Biogen suggests potential precedents in past coverage decisions for upcoming Medicare determination on Aduhelm and other amyloid-directed monoclonal antibodies during earnings call.
You may also be interested in...
Eisai/Biogen’s Lecanemab: Pricing Pressure Builds Ahead Of Likely US Approval Of Alzheimer’s Drug
After the commercial and public relations debacle driven by Biogen’s original pricing for the companies’ predecessor drug for Alzheimer’s, Aduhelm, Eisai is feeling the heat to ensure the US price for lecanemab is in line with stakeholder expectations.
Medicare Draft NCD For Alzheimer's Drugs: When 'Reasonable And Necessary' And 'Safe And Effective' No Longer Align
Proposed decision withholds Medicare coverage from current and future amyloid-directed monoclonal antibody drugs for Alzheimer’s disease unless patients are enrolled in a randomized clinical trial.
Aduhelm Price Cut May Help Pave The Way For Medicare National Coverage Determination
With CMS draft decision expected next month on amyloid-clearing antibodies for Alzheimer’s, Biogen slashes Aduhem’s price 50% to $28,200 per year. Move reverses another aspect of the approval that drew criticism, including the expansive label and long horizon for confirmatory data.